Trial Profile

Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of ACT-293987 in Patients With Pulmonary Arterial Hypertension

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selexipag (Primary)
Indications Pulmonary arterial hypertension
Focus Adverse reactions
Acronyms GRIPHON OL
Sponsors Actelion Pharmaceuticals

Most Recent Events

03 Jan 2022 Status changed from active, no longer recruiting to completed.
26 Nov 2021 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.
15 Nov 2021 Planned number of patients changed from 670 to 1150.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com